122 related articles for article (PubMed ID: 20668267)
1. Approval of provenge seen as first step for cancer treatment vaccines.
Brower V
J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
[No Abstract] [Full Text] [Related]
2. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
3. Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
Chambers JD; Neumann PJ
N Engl J Med; 2011 May; 364(18):1687-9. PubMed ID: 21470004
[No Abstract] [Full Text] [Related]
4. Concerns about Provenge simmer as CMS ponders coverage.
Goozner M
J Natl Cancer Inst; 2011 Feb; 103(4):288-9. PubMed ID: 21303996
[No Abstract] [Full Text] [Related]
5. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
Moyad MA
Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606
[TBL] [Abstract][Full Text] [Related]
6. FDA approves prostate cancer "vaccine".
Tanne JH
BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
[No Abstract] [Full Text] [Related]
7. Landmark approval for Dendreon's cancer vaccine.
DeFrancesco L
Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312
[No Abstract] [Full Text] [Related]
8. Dendritic cell vaccine hits FDA roadblock.
Morrow T
Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
[No Abstract] [Full Text] [Related]
9. Provenge approval means sensitive coverage decisions.
Silverman E
Manag Care; 2010 Sep; 19(9):31-4. PubMed ID: 20931888
[No Abstract] [Full Text] [Related]
10. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
11. The regulator disapproves.
Nat Biotechnol; 2008 Jan; 26(1):1. PubMed ID: 18182998
[No Abstract] [Full Text] [Related]
12. Fallout from flip-flops.
Froese P
Nat Biotechnol; 2008 Jun; 26(6):614-5. PubMed ID: 18536677
[No Abstract] [Full Text] [Related]
13. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S; Toumi M
BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
[TBL] [Abstract][Full Text] [Related]
14. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product.
Baghdadi R
Oncology (Williston Park); 2010 Sep; 24(10):881-3. PubMed ID: 21138168
[No Abstract] [Full Text] [Related]
15. Abigail Alliance v. Von Eschenbach: restricting access to potentially lifesaving drugs singe 2007.
Goodman AJ
J Contemp Health Law Policy; 2008; 25(1):107-41. PubMed ID: 19137749
[No Abstract] [Full Text] [Related]
16. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity.
Bot A
Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923
[No Abstract] [Full Text] [Related]
17. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Madan RA; Gulley JL
Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262
[TBL] [Abstract][Full Text] [Related]
18. Is Provenge Angst a symbol or symptom of the times?
Holcombe DG
Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
[No Abstract] [Full Text] [Related]
19. Cancer vaccines on the horizon.
Jones D
Nat Rev Drug Discov; 2007 May; 6(5):333-4. PubMed ID: 17539052
[No Abstract] [Full Text] [Related]
20. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
Gaines KK
Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
[No Abstract] [Full Text] [Related]
[Next] [New Search]
